Literature DB >> 20437867

Prognostic factors in cancer of unknown primary site.

Maria Jose Fernandez-Cotarelo1, Juan Manuel Guerra-Vales, Francisco Colina, Javier de la Cruz.   

Abstract

AIMS AND
BACKGROUND: Patients with cancer of an unknown primary site (CUP) usually have a poor outcome. The identification of prognostic factors that affect survival can help clinicians find a better approach to such cases in terms of diagnostic and therapeutic management.
METHODS: We conducted a retrospective study including the cases of CUP recorded at the University Hospital 12 de Octubre Tumor Registry between 1999 and 2003.
RESULTS: CUP was diagnosed in 265 patients during the analyzed period. One hundred and seventy-one were men (64.5%) and the mean age of the patients was 66.9 years (range 32-98 years). The median survival was 2.5 months, and the survival rate was 35.1% 6 months from diagnosis (95% CI: 28.9-41.3) and 24.5% 1 year from diagnosis (95% CI: 18.7-30.3). Univariate analysis revealed as significant predictive variables of a better outcome age under 70 years; involvement of a single organ; normal serum levels of alkaline phosphatase and albumin; normal erythrocyte sedimentation rate; normal levels of the serum tumor markers CEA, CA 19.9 and CA 15.3; squamous carcinoma histology; clinical presentation as lymph node enlargement; and the administration of treatment. Multivariate analysis showed that albumin and alkaline phosphatase levels, squamous carcinoma histology, age and treatment were the most important prognostic factors. Other variables analyzed (liver, bone or lung involvement, lactate dehydrogenase levels, gender) did not affect survival.
CONCLUSIONS: CUP has a poor prognosis. Some prognostic factors that affect survival in these patients, however, may be identified.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437867     DOI: 10.1177/030089161009600118

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  8 in total

1.  Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary.

Authors:  Umut Elboga; Selim Kervancioğlu; Ertan Sahin; Mustafa Basibuyuk; Y Zeki Celen; Cumali Aktolun
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

2.  Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

Authors:  Malek B Hannouf; Chander Sehgal; Jeffrey Q Cao; Joseph D Mocanu; Eric Winquist; Gregory S Zaric
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

3.  Squamous cell carcinoma of unknown primary site presenting with an abdominal wall lesion as the primary symptom: A case report and review of the literature.

Authors:  Yingli Zhang; B O Chen; Jianqing Zhu; L U Chen
Journal:  Oncol Lett       Date:  2015-07-21       Impact factor: 2.967

4.  Efficacy of 18F-FDG PET/CT in investigation of elevated CEA without known primary malignancy.

Authors:  Simon Sin-Man Wong; Wong L Yu; Ki Wang; Anil T Ahuja
Journal:  Indian J Radiol Imaging       Date:  2016 Jul-Sep

5.  Advantages and disadvantages of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary.

Authors:  Xiaozhou Yu; Xiaofeng Li; Xiuyu Song; Dong Dai; Lei Zhu; Yanjia Zhu; Jian Wang; Huiqin Zhao; Wengui Xu
Journal:  Oncol Lett       Date:  2016-09-29       Impact factor: 2.967

6.  Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis.

Authors:  Yizi Jin; Mingxi Lin; Zhiguo Luo; Xichun Hu; Jian Zhang
Journal:  Ann Transl Med       Date:  2021-02

7.  The Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Evaluation of Bone Lesions of Undetermined Origin.

Authors:  Cuneyt Tamam; Muge Tamam; Mehmet Mulazimoglu
Journal:  World J Nucl Med       Date:  2016 May-Aug

8.  Detection efficiency of 18F-flourodeoxyglucose positron emission tomography/computed tomography for primary tumors in patients with carcinoma of unknown primary.

Authors:  Nosheen Fatima; Maseeh Uz Zaman; Areeba Zaman; Unaiza Zaman; Sidra Zaman; Rabia Tahseen
Journal:  World J Nucl Med       Date:  2019-07-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.